Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB-210 is a recombinant protein therapeutic developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. Originally investigated for the treatment of cystic fibrosis, it has been repurposed as a potential therapy for COVID-19. The drug is designed to inhibit the entry of the SARS-CoV-2 virus into host cells by acting as a soluble decoy or by interfering with the interaction between the viral spike protein and the host cell receptors. Clinical development in Cuba has progressed to Phase 2 trials to evaluate its safety and efficacy in patients with COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CIGB-210 (Center for Genetic Engineering and Biotechnology).